Each vial contains highly pure lyophilized Retatrutide.
Retatrutide is classified as a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors), making it more effective for body fat mass reduction than its predecessors Tirzepatide and Semaglutide by targeting further receptors. Unlike Wegovy (GLP-1) or Mounjaro (GIP/GLP-1), Retatrutide is the first to add a Glucagon agonist, actively increasing energy expenditure and fat metabolism, not just suppressing appetite.
Unauthorized health products have not been approved by Health Canada and may pose serious health risks. These are explicitly for research use only.
Each vial contains highly pure lyophilized Retatrutide.
Retatrutide is classified as a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors), making it more effective for body fat mass reduction than its predecessors Tirzepatide and Semaglutide by targeting further receptors. Unlike Wegovy (GLP-1) or Mounjaro (GIP/GLP-1), Retatrutide is the first to add a Glucagon agonist, actively increasing energy expenditure and fat metabolism, not just suppressing appetite.
Unauthorized health products have not been approved by Health Canada and may pose serious health risks. These are explicitly for research use only.